Mice rendered deficient in IL-1[3 by gene targeting in embryonic stem cells develop and grow normally in a protected laboratory environment. Endotoxin-stimulated peritoneal macrophages from IL-l~-deficient mice showed normal synthesis and cellular release of IL-lct after treatment with 5 mM ATP demonstrating that IL-113 is not necessary for expression and release of the IL-lot isoform. Mice deficient in IL-I~ showed unaltered sensitivity to endotoxic shock, with or without pretreatment with D-galactosamine. In contrast, IL-lJ3-deficient mice showed defective contact hypersensitivity responses to topically applied trinitrochlorobenzene (TNCB). This defect could be overcome either by application of very high doses of sensitizing antigen, or by local intradermal injection of recombinant IL-1[3 immediately before antigen application. These data demonstrate an essential role for IL-1[3 in contact hypersensitivity and suggest that IL-1{3 acts early during the sensitization phase of the response. They suggest an important role for 1I.-1(3 in initiation of the host response at the epidermal barrier.
T
he potent proinflammatory cytokine interleukin-1 (IL-1) is synthesized in two isoforms (designated IL-la and IL-1[3) encoded by distinct, chromosomally linked genes (1) (2) (3) . Both forms of IL-1 are synthesized as 31-kD intracellular precursors that are cleaved to the 17-kD mature cytokines found in culture supernatants and extracellular fluids (4) . The maturation of the IL-la precursor is thought to be dependent on the calcium-activated proteinase calpaln (5) , whereas the maturation of the IL-1[~ precursor is dependent on the cysteine proteinase IL-lJ~-converting enzyme (ICE) 1 (6) . Two cell surface receptors for IL-1 have been defined (7) (8) (9) , designated IL-1RI and ILlP, II. Mature IL-la and IL-lJ3 bind similarly to these two defined receptors (10) and, consequently, demonstrate the same activities in a broad range of in vitro and in vivo biological systems.
The ability of the IL-1 proteins to modulate the normal and pathological physiology of essentially all tissues is a 1Abbreviations used in this paper: ES, embryonic stem; ICE, IL-l[~-converting enzyme; IL-lra, IL-1 receptor antagonist; LT, lymphotoxin; PEC, peritoneal exudate cells; TNBS, trinitrobenzene sulfonate; TNCB, trinitrochlorobenzene.
Dr. De Togni's current address is Department of Pathology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AlL 72205.
consequence of the broad expression of the defined IL-1 receptors. Based on studies of the action of the cytokines in vitro and following their administration to experimental animals in vivo, IL-1 is thought to potentiate inflammatory responses and to promote tissue repair (4) . These studies, however, define only the potential actions of IL-1 in normal and pathological responses. Studies defining the physiological responses in which IL-1 acts in an obligatory fashion remain incomplete. Definition of the essential functions oflL-1 in vivo is complicated by the fact that many of the actions of IL-1 defined in vitro are shared with other cytokines, particularly with IL-6, tumor necrosis factor (TNF) and lymphotoxin (LT) (4, 11, 12) . Furthermore, in many tissues these cytokines regulate each other's expression, forming a potentially complex and interactive cytokine network (13) .
There has been considerable progress in defining the essential functions oflL-1 in vivo by using either neutralizing monoclonal antibodies (against IL-1 or against the IL-1 receptors) (14) (15) (16) , soluble IL-1 receptors (17) , or the naturally occurring IL-1 receptor antagonist (IL-lra) (18) to block IL-1 action in experimental animal models. Using these approaches, IL-1 has been implicated as a significant mediator in the generation of fever (19) and acute inflammatory responses (20). IL-1 also contributes fundamentally in the normal host response against infection by Listeria monocytogenes (16) . This action oflL-1 is at least in part dependent on actions of this cytokine in the recruitment of neutrophils and in the activation of macrophages (21).
Few studies of this nature, however, have demonstrated unique roles for either of the IL-1 agonist isoforms. Studies by Geiger et al. (22) and Van den Berg et al. (23) have suggested a selective role for IL-113 in the initiation and progression of collagen-induced arthritis in mice. A fundamental action of IL-1 has also been suggested in a transgenic model ofpetipheral arthritis due to aberrant expression of TNFct (24).
An additional selective role for IL-1[3 has been proposed in the development of contact hypersensitivity responses in the skin (25, 26) . Contact sensitizers increase the levels of mRNA for several cytokines in the skin, including IL-lct, IL-113, and TNFcx. IL-113 m.R2qA is increased first, being detected within 15 min aRer application of the sensitizing agent. Selective depletion of individual epidermal cell populations suggests that Langerhans cells are the primary source of IL-113, and that keratinocytes are the primary source oflL-lcx (27). The regulatory specificity oflL-l[3 in contact hypersensitivity responses was suggested by studies in which intradermal injection of monoclonal anti-murine IL-113 antibodies prevented primary sensitization (26). In contrast, anti-IL-lct antibodies did not interfere with sensitization.
New insights into the in vivo action oflL-l[3 have come from studies using mice rendered genetically deficient in this cytokine by gene targeting in embryonic stem cells (28). These studies have demonstrated that IL-113 is an essential mediator of the systemic response following subcutaneous injection of turpentine. Mice deficient in IL-I[~ failed to demonstrate the typical anorexic and febrile responses that follow this maneuver. They also showed an impaired turpentine-induced acute phase response, with failure of induction of plasma IL-6. Plasma IL-6 levels were, however, indistinguishable in normal and IL-l[3-deficient mice after challenge with lipopolysaccharide (LPS), indicating that there was no absolute defect in IL-6 production. This study demonstrated a selective role for IL-113 in activating the systemic response to subcutaneous injection of turpentine, and established unequivocally that IL-113 and IL-lct can act independently in vivo.
We report here the independent production of a mouse strain deficient in IL-113, and experiments demonstrating an essential action of IL-113 in contact hypersensitivity responses to trinitrochlorobenzene (TNCB). This action of IL-113 appears to be expressed at the early times of local sensitization, as normal contact hypersensitivity responses can be restored by intradermal injection of recombinant murine IL-113 locally immediately before the application of the sensitizing antigen. These data establish a critical role for IL-113 in the initiation of the systemic immune response to this agent after sensitization at epidermal surfaces. ited with thioglycollate broth and plated at 1.5 • 106 ceUs/ml as previously described (35) . Following adherence overnight, the PEC were incubated either in the presence or absence of 1 p~g/ml E. coli LPS for 4 h, and RNA was isolated using a modification of the guanidinium isothiocyanate/CsC1 method (36) as described (35) . Hybridization was with 32p-labeled near full-length fragments of the IL-lot (37) and IL-113 (38) cDNAs labeled using the random priming method. Metabolic Labeling and Imraunoprecipitation. PEC harvesting, culture, pulse-chase labeling using 3SS-met, and immunoprecipitation were performed as previously described (15) with hamster anti-mouse IL-lct and anti-mouse IL-1B monoclonai antibodies 161.1 (14) and B122 (15) . Measurement oflL-1 by ELISA. IL-lct and IL-1B were measured using commercial ELISA kits (Genzyme, Cambridge, MA) according to the manufacturer's instructions. PEC were incubated and culture supematants and cell lysates were prepared as described for metabolic labeling and immunoprecipitation. CeU lysates were centrifuged for 10 rain at 4~ in an Eppendoffmodel 5414 microcentrifuge before assay. Endotoxic Shock. Endotoxic shock was induced by two different protocols. In the first, age-matched mice were injected i.p. with 20 mg D-galactosamine and 10 g~g E. coli LPS (0111:B4) in 0.5 ml sterile PBS. Lethal responses were always observed within the first 12 h following injection. Mice that survived were observed for 1 wk and appeared to recover completely. In the second protocol, 8-12-week-old mice received 1.5 mg LPS (0127: B8) in 0.5 ml sterile PBS by i.p. injection.
Materials and Methods

IL-lfl
Contact Hypersensitivity. Reactivity to T N C B was determined using a modification of the method of Ferguson et al. as previously described (39) . Briefly, 8-12-week-old IL-113 deficient mice and their wild-type littermates were prepared by shaving their abdomens and then varying doses of TNCB (Eastern Chemical, Smithtown, NY) were applied in 25 ~ olive oil/acetone (1:3). 5 d later, the mice were challenged by injection of 33/~1 of 10 mM TNBS (Sigma) into the right footpad. The same volume of PBS was injected into the left footpad as a negative control. 24 h hter, footpad swelling was measured by a blinded observer and expressed as the thickness of the right footpad minus the thickness of the left footpad. Where indicated, recombinant murine IL-113 was injected intradermaUy at the sensitization site immediately before the application of TNCB. 1Leactivity to oxazolone was determined as previously described (28). Lymphocyte Proliferative Responses. Lymphocytes were isohted from the axillary and inguinal lymph nodes of TNCB-sensitized mice. Cells from four mice treated in a similar fashion were pooled and 5 • 10 s cells were cultured in triplicate in 96-well flat-bottom microtiter phtes in 100 IX1 R.PMI 1640 (GIBCO BILL) with 10% heated fetal calf serum, glutamine, 2-mercaptoethanol, penicillin, and streptomycin. Each well also contained from 0-4 • 10 s 2,4,6-trinitrophenyl (TNP)-coupled, mitomycin-C-treated spleen cells from wild-type sv129 mice (Jackson Laboratories, Bar Harbor, ME). After 78 h of culture, 1 mCi (37 kBq) of [3H]thymidine (DuPont NEN, Boston, MA) was added to each well, and 18 h later, cells were harvested using a PhD cell harvester (Cambridge Technology, Inc., Watertown, MA), and incorporation of radioactivity determined by liquid scintillation counting as previously described (39) .
Results and Discussion
Generation oflI.,-l~-deficient Mice. The IL-I[~ gene is encoded in seven exons (40) . To create a mouse strain carrying a null allele at this locus, we generated a targeting vector in which exon 4 was interrupted by insertion of the PGKneo sequence (31) . This introduced an in frame termination codon upstream of the ICE cleavage site encoded in exon 5, precluding the translation of the receptor-binding domain of the protein. The vector contained 3.4 kb of sequence homologous to the IL-113 gene upstream of the neo cassette, and 1.1 kb of homologous sequence downstream of neo, with HSV-tk included upstream of the 3.4-kb arm for negative selection (30) (Fig. 1 a) . After homologous recombination in embryonic stem (ES) cells, the wild-type 5.9-kb IL-113 BamHI fragment was replaced by a 7.5-kb fragment in the targeted allele (Fig. 1 b) .
This construct was introduced into D3 ES cells by dectroporation and homologous recombinants were selected using ganciclovir and G418. Homologous recombinants were detected at a frequency of ,'ol in 100 double drugresistant colonies. One targeted D3 line passed the targeted allele through the germ line. Matings of heterozygous IL-113--deficient mice confirmed the results of Zheng et al.
(28) that homozygous mutant mice were obtained at a frequency ofl in 4, indicating that a normal IL-113 gene is not required for successful embryonic development. The structure of the targeted locus was confirmed by Southern blotting using as the probe a fragment of the IL-113 gene derived from a portion of the 5th intron external to the targeting vector (Fig. 1 a) . Hybridization with a neo probe confirmed that there was only a single integration event (Fig. 1 b) . Again confirming the results ofZheng et al. (28), IL-113-deficient mice displayed a grossly normal phenotype, demonstrating that IL-113 is not essential for posmatal development.
The development of cells of the hematopoietic lineage was assessed by flow cytometry and histological analysis. IL-113-deficient and wild-type mice did not differ significantly in the numbers of peripheral blood erythrocytes, lymphocytes, monocytes, neutrophils, or platelets (data not shown). Similarly, the cell content and architecture of the spleen and thymus were grossly similar in IL-l~-deficient and wildtype mice (data not shown).
Evaluation oflL-1 Expression. Functional ablation of the IL-113 gene was confirmed by Northern blotting, immunoprecipitation, and ELISA. PEC were elicited by i.p. injection of thioglycollate. 3 d afEer thioglycollate injection, exudate cells were harvested by peritoneal lavage. Similar numbers of macrophages were recovered from the wildtype and the IL-113-deficient mice, demonstrating that macrophage recruitment to the peritoneal cavity can occur in the absence of this cytokine.
PEC from wild-type, heterozygous, and IL-113-deficient mice were incubated for 4 h in the presence or absence of LPS. By Northern blotting, there was no detectable IL-l{3 mRNA in LPS stimulated PEC from the IL-113-deficient mice (Fig. 1 c) . IL-113 mRNA was present at an intermediate level in LPS-stimnlated PEC from mice heterozygous for IL-I~ deficiency. Given that the mutant IL-113 gene carried alterations limited to exon 4, and that this exon is not known to affect expression of the IL-113 gene, we speculate that the absence of detectable IL-113 transcripts in IL-113-deficient mice represents dramatic destabilization of the IL-113 mtLNA rather than obliteration of IL-113 transcription. Hybridization with an IL-lot eDNA probe showed indistinguishable induced levels of LPS-induced IL-la transcripts in wild-type, heterozygous, and IL-113-deficient mice Fig. 1 c) . This confirmed that PEC from IL-1l~-deficient mice retained responsiveness to LPS and that LPS-induced expression of IL-la was not dependent on expression of IL-113.
Analysis of IL-1 biosynthesis by pulse-chase labeling and immunoprecipitation confirmed that IL-l{3 protein was undetectable in mice homozygous for IL-I~ deficiency (Fig. 2 a) . In contrast, biosynthesis ofpro-IL-la was indistinguishable in wild-type and IL-113-deficient mice (Fig. 2  b) . In normal LPS-stimulated macrophages, induction of cdluhr apoptosis by treatment with 5 mM ATP is known to trigger efficient maturation of both IL-1 isoforms and their release from the cell (41) . Consequently, we treated LPSstimulated PEC from wild-type and IL-l~-deficient mice with ATP and evaluated the processing and release of IL-lot (Fig. 2, a and b) . The ATP-induced release of mature IL-hx from wild-type and IL-l[3,-deficient cells was also indistinguishable. This demonstrated that release of IL-la was not dependent on IL-I~. This is in contrast to data obtained in ICE-deficient mice in which in addition to the expected Thus, as assessed by Northern blotting, pulse-chase labeling and immunoprecipitation, and ELISA, gene targeting resulted in complete functional ablation of the I L -I~ locus. All of the data suggested that normal expression and cellular release of IL-let were retained. This distinguishes the biochemical characteristics of the IL-l~r-deficient strains from ICE-deficient strains in which I L -I~ biosynthesis is unaffected, but the release of IL-lct from activated cells is substantially reduced (42, 43) .
Unaltered Sensitivity to Endotoxic Shock in IL-lfl-defident Mice. Treatment of normal mice with high doses ofendotoxin results in the production and release of several proinflammatory cytokines, including TNF, IL-1, IL-6, and IFN-~/. These, in turn, appear to be the major mediators of the lethal effects of endotoxin (44) . Blocking the action of these cytokines reduces endotoxin-induced mortality as evidenced by endotoxin resistance in TNF receptor type 1-deficient (45), IFN-~/ receptor-deficient (46) , and ICE-deficient mice (42) . In addition, administration of the IL-lra to both mice (47) and rabbits (48) protects from the lethal effects ofendotoxic shock.
The sensitivity of IL-lJ3-deficient and wild-type mice to endotoxin was determined both with pretreatment with D-galactosamine (data not shown) and without galactosamine ( (open circles) and eight wild-type (closed drdes) mice received 1.5 mg E. coli LPS (0127:B8) in sterile PBS by i.p. injection.
Susceptibility to endotoxic shock. Groups of eight IL-lJ3 -/-interest in light of the defined resistance to endotoxin conferred by treatment with the IL-lra and by inherited deficiency of ICE. As ICE-deficient and IL-lra-treated mice have defects in function of both IL-113 and IL-lot, whereas IL-l[3-deficient mice retain IL-lct expression and release, these data support a significant role for IL-loc in systemic endotoxemia.
IL-1~ Is Required for Normal Contaa Hypersensitivity Responses.
In order to test the role of IL-113 in contact hypersensitivity responses, we examined responsiveness in wild-type and IL-l[3-deficient mice after sensitization with varying concentrations of TNCB. Sensitization of wild-type mice with 25 p,1 of TNCB ranging in concentration from 0.01 to 3.0% lead in a dose-dependent fashion to antigen-specific swelling at the sight of challenge 24 h after subcutaneous injection of 10 mM TNBS into the footpad. Significant footpad swelling was detected after sensitization with 0.03% TNCB, and maximal swelling was observed after sensitization with 0.1% TNCB (Fig. 4) . In contrast, mice deficient in IL-1B showed no footpad swelling following sensitization with 0.1% TNCB, requiring 1% TNCB to achieve a response equivalent to the wild-type mice. Histological evaluation of the sites of antigen challenge showed an inflammatory cell infiltrate in wild-type mice sensitized with 0.1% TNCB compared to nonsensitized controls (Fig. 5, a  and b) , but no detectable infiltrate in sensitized IL-l[3-deficient mice (Fig. 5 c) . Similarly, when cells were isolated from the axillary and inguinal lymph nodes draining the site of sensitization and incubated with TNBS-haptenated spleen cells, dose-dependent proliferation was detected with cells from wild-type mice sensitized with 0.1% TNCB, whereas no specific proliferation was detected in IL-l[3-deficient mice treated with this same concentration of sensitizing antigen (Fig. 6) . Lymphocytes from nonsensitized wild-type mice or wild-type mice sensitized with low doses of TNCB (0.01 and 0.03%) did not proliferate in response to TNBShaptenated spleen cells (data not shown). These data suggest, then, that the proliferative response in sensitized wildtype mice represented T cell priming in vivo. Together, these data all demonstrate a significant defect in the ability of IL-l[3-deficient mice to manifest a contact hypersensitivity reaction.
Zheng et al. previously reported that in an independently derived IL-l[3--deficient mouse strain the contact hypersensitivity response to oxazolone was normal (28). We tested the response to topical oxazolone in the IL-I[3-deficient strain described here. Wild-type and IL-l[3-deficient mice were sensitized by topical application of oxazolone (100 ml of 0.01%, 0.04%, 0.1%, 0.4%, 1%, and 4%) to the shaved abdomen and 5 d later sensitivity was tested by application of 50 p,1 of 1% oxazolone to the ear. After an additional 24 h, the degrees of ear swelling were indistinguishable in wild-type and IL-l[3-deficient mice (data not shown). These data are in dramatic contrast to results using TNCB and suggest that the cutaneous responses to these two antigens are not equivalent. Although the mechanism remains undefined, differences in the methods to elicit the hypersensitivity response may underlie the differences in the TNCB and the oxazolone responses. For example, we measured hypersensitivity to TNCB following injection of soluble TNBS into the footpad, whereas hypersensitivity to oxazolone was measured following topical application to the ear. Thus, the mechanism by which eliciting antigen is detected in the footpad and the ear may not be identical. Additionally, TNCB was applied at the time of sensitization as a solution of 25% olive oil in acetone, whereas oxazolone was applied dissolved in acetone alone. Thus, the local handling of the sensitizing antigen may be different for the two antigens. Finally, it remains possible that the cellular constituents responsible for TNCB and oxazolone reactivity are not the same. Regardless, the data presented here demonstrate a dramatic requirement for IL-113 in the response to TNCB. To investigate at which stage of the TNCB response IL-113 exerted its action, we injected purified recombinant murine 17 kD IL-113 (rlL-l[3) (49) intradermally immediately before sensitization at the site where the sensitizing antigen was to be applied. Pretreatment with rlL-l[3 but not with saline resulted in dose-dependent restoration of responsiveness to antigen challenge five days later (Fig. 7) and a restoration of the inflammatory cell infiltrate examined histologically (Fig.  5 d) . These data support a role for IL-113 specifically during the sensitization phase of the contact hypersensitivity response. Sensitization of the IL-l[3-deficient mice is, however, demonstrated when high concentrations of antigen are applied to the skin. We speculate that this indicates that IL-113 acts on or through cells whose role is to enhance antigen uptake, processing, or delivery to the antigenresponding cells and that high doses of antigen bypass these functions. Both Langerhans cells and keratinocytes have been shown to express IL-l[3 in the epidermis (26, 27). Using mononuclear phagocytes, we have demonstrated that induction of cellular apoptosis in vitro leads to rapid release ofbioactive IL-113 (41) . O u r current data suggest either that these Langerhans cells or keratinocytes possess a novel mechanism for IL-113 release that is expressed in situ in the skin, but not in vitro, or that apoptosis o f the IL-1 [3-producing cell is a characteristic of contact hypersensitivity responses. Ahernatively, they may imply the presence o f a novel IL-1 receptor in skin that can interact with unprocessed 31 kD pro-IL-l[3 as an activating hgand, or that may have specificity for IL-113, perhaps not recognizing IL-loc A precedent for a receptor that can discriminate IL-113 from IL-loL Our observation that IL-l[3 plays a dramatic role in contact hypersensitivity responses to TNCB at low to moderate doses of sensitizing antigen caution against excluding an activity of this or any cytokine in a physiological response by experiments using high levels of stimuli. Although we have not defined the mechanism by which high doses of sensitizing antigen overcome the defect in the contact hypersensitivity response in IL-lJ3--deficient mice, the use of low doses of sensitizing antigen may uncover a role for IL-113 in lowering the threshold for responsiveness. Conversely, high doses of sensitizing antigen may circumvent the fundamental character of the response being analyzed.
In summary, we report the generation of a mouse strain rendered deficient in expression of IL-113 by gene targeting. This strain confirms that IL-1[3 is not required for viable embryonic development or normal post-natal growth. Analysis of this strain discloses no evidence of an obligatory role for IL-I~ in lymphoid cell development or in the development of other bone-marrow derived cells. Additionally, absence of IL-113 does not alter the sensitivity to endotoxin-induced death in two models of endotoxic shock. Deficiency of IL-113 does, however, result in a defect in contact hypersensitivity responsiveness to TNCB, with this effect expressed at the level of sensitization. Additional evaluation of this strain will permit definition of the cellular elements in the epidermis that mediate this effect. It will also permit definition of whether IL-1[3 acts selectively in the epidermis, or generally in sensitization at all epithelial surfaces, particularly in the respiratory and gastrointestinal tracts. As such, this IL-lj3-deficient mouse strain may prove valuable in identifying new targets with clinical relevance to human hypersensitivity disease.
